



Human Anti-Brentuximab vedotin monoclonal antibody, clone AbD39659ia (CABT-ZB1152)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Specificity	Brentuximab Vedotin
Target	Brentuximab
Immunogen	Brentuximab vedotin
Isotype	lgG1, κ
Source/Host	Human
Species Reactivity	N/A
Clone	AbD39659ia
Affinity Constant	The monovalent intrinsic affinity of AbD39659ia was measured as KD = 1.4 nM by real time, label free molecular interaction analysis on immobilized brentuximab vedotin.
Purification	Protein A purified
Conjugate	Unconjugated
Applications	Suitable for use in ADA bridging ELISA. Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded.
Format	Liquid
Concentration	Lot specific
Size	100 μg

45-1 Ramsey Road, Shirley, NY 11967, USA

Tel: 1-631-624-4882 Fax: 1-631-938-8221

Buffer	PBS
Storage	Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Ship	Wet ice

BACKGROUND

Introduction	Brentuximab vedotin (Adcetris) is a chimeric mouse/human IgG1 kappa ADC, approved by the FDA for the treatment of Hodgkin's lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL). The brentuximab antibody selectively targets tumor cells expressing the cell membrane protein CD30, and delivers the conjugated toxin, monomethyl auristatin E (MMAE). Once inside the cell the MMAE is released from the antibody by proteolytic cleavage and disrupts the microtubule network inducing cell cycle arrest and apoptosis of the malignant cells, thereby preventing tumor growth and proliferation.
Keywords	Brentuximab vedotin; Adcetris